TickerTalks
Browse all tickers →
TickerTalks›$EXEL
EXEXEL

Exelixis, Inc.

Strong FundamentalsStrong FundamentalsRevenue growing 11% YoY at strong marginsStreet coverage with positive forward estimatesQuiet on X (69 mentions/wk)
$EXEL·$14B·Biotechnology·Healthcare
$57.49+1.3%YTD+30.5%1Y+45.1%
Price updated 6m ago·X counts updated 4d ago
EXEXEL
$EXELExelixis, Inc.
$57.49+1.25%69 posts1.1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $EXEL on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

69X posts · last 7 days
Sep 3Sep 13
Chatter Meter
1.1×
QuietNormal · 1×Loud

How loud $EXEL's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 75% of tracked names.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $EXEL — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersWinding up for a moveAI verdict · as of 2026-09-16

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Cabozantinib patents just held on appeal blocking generics to 2030 as zanzalintinib PDUFA slides to March 2027.

Exelixis has two big regulatory wins offsetting one delay. The Federal Circuit affirmed three cabozantinib patents on August 31 (blocking MSN Laboratories' generic entry until at least January 15, 2030), and Farallon disclosed a 5.6% stake. The FDA extended zanzalintinib review by three months to March 3, 2027 — a delay but not a clinical deficiency signal.

  • Q2 revenue of $629M grew 10.6% YoY, gross margin of 96.7%, and operating margin of 39.5% — the specialty-oncology model prints cash.
  • Trailing P/E of 17.5x with FY26 EPS consensus of $3.51 (walking to $4.12 in FY27 and $4.97 in FY28) puts forward P/E in the mid-teens — reasonable for a biopharma still growing.
  • Position at 89% of the 52-week range on a 78% growth rate, ROIC of 38%, and ROE of 42% confirm this is a high-quality specialty-oncology franchise, not a story stock.

Cabometyx NET (neuroendocrine-tumor) growth ramp is the near-term watch item; zanzalintinib launch is now Q1 2027.

What to watch: November 3 earnings, NET indication uptake, November 2026 fourth-patent trial, March 3 2027 PDUFA date.

On the calendar: Earnings 2026-11-03

low x chatter

Read the AI verdict on $EXEL

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Oncology biotech commercializing cabozantinib (Cabometyx) for kidney, liver, and thyroid cancers with a growing internal pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $EXEL.

Biotechnology · Healthcare

mRNA oncology platform is the week's catalyst — Merck CEO hinted positive MRNA melanoma Phase 3 data (Oct readout, potentially doubling cancer-free rate vs Keytruda), driving MRNA +8%. IBB +41% T12M reflects the GLP-1, gene-editing, and RNA-medicine premium multiples re-rating the sector. ALT +14.2% since earnings confirms GLP-1 pipeline names as the most active near-term catalyst cohort.

What this means for $EXEL

Partial — cabozantinib (CABOMETYX) for renal cell carcinoma and hepatocellular carcinoma is a commercial oncology product that benefits from the oncology platform re-rating; stable revenue base limits pure-biotech sentiment leverage but provides fundamental support.

Top industry ETF

$IBBiShares Biotechnology ETF
+19.3%YTD
+43.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
17.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
37.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
39.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
8.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
42.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
96.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$0.91$0.85+6.7%
Q1 2026May 5, 2026$0.87$0.77+13.7%
Q4 2025Feb 10, 2026$0.94$0.77+22.1%
Q3 2025Nov 4, 2025$0.78$0.69+13.9%
Next earningsTue, Nov 3·consensus EPS $0.89

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$628.7M+10.6%96.7%39.5%$0.85$309.8M
Q1 FY26$610.8M+10.0%96.7%41.1%$0.81$249.8M
Q4 FY25$598.7M+5.6%95.6%39.3%$0.91$332.4M
Q3 FY25$597.8M+10.8%96.9%39.6%$0.72$288.8M

Forward consensus

5-year forecast · up to 14 analysts
FYRevenueRangeEPSRangeAnalysts
FY27$2.6B$2.5B – $2.6B$3.51$3.36 – $3.5813
FY28$2.9B$2.8B – $3.0B$4.12$3.61 – $4.8513
FY29$3.3B$2.4B – $3.6B$4.97$3.88 – $6.3414
FY30$3.5B$3.3B – $3.7B$5.65$5.10 – $6.017
FY31$3.1B$2.9B – $3.3B$4.73$4.27 – $5.036

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.89%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+2.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+17.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 204.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 10Mary C BeckerleDirector9.8K sh$527KSellJun 1Jack L WyszomierskiDirector3.9K sh$198KSellJun 1Eckhardt Sue GailDirector9.8K sh$492KSellMay 26Dana AftabEVP, Research and Development43.5K sh$2.2MSellMay 20Patrick J. HaleyEVP, Commercial32.1K sh$1.6MSellMay 18Brenda HeftiSVP and General Counsel6.6K sh$333KSellMay 18Christopher J. SennerCFO34.9K sh$1.7MSellMay 7Mary C BeckerleDirector7.7K sh$374KSellMay 7Maria C FreireDirector20.6K sh$949KSellMay 7George PosteDirector60.0K sh$2.7M
+ 19 other (10 awards · 5 inkinds · 2 gifts · 2 exempts) in window

See when $EXEL insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentAug 14SC 13D/A
AI summary

Farallon Capital Management and related entities filed an SC 13D/A on Exelixis (EXEL) disclosing shared beneficial ownership of 13,989,010 shares equal to 5.6% of outstanding common stock. The shared-only voting and dispositive structure reflects ownership spread across multiple Farallon fund vehicles.

8-KOfficer or director changeMay 298-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
+ 13 other (3 13Gs · 3 proxys · 2 routine 8-Ks · 2 10-Qs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com·2d agoExelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdlemarketbeat.com·2d agoHere's Why Exelixis (EXEL) is a Strong Growth Stockzacks.com·3d agoIntegrated Wealth Concepts LLC Has $3.19 Million Stock Holdings in Exelixis, Inc. $EXELdefenseworld.net·3d agoExelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchisesmarketbeat.com·3d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALT$MRNA$AURA$NWBO$IBRX$SLS$IOVA$CMPS
Voices on X · last 7 days

No standout posts about $EXEL on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport